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Abstract: Specialized compounds from photosynthetic organisms serve as rich resources 
for drug development. From aspirin to atropine, plant-derived natural products have had a 
profound impact on human health. Technological advances provide new opportunities to 
access these natural products in a metabolic context. Here, we describe a database and 
platform for storing, visualizing and statistically analyzing metabolomics data from 
fourteen medicinal plant species. The metabolomes and associated transcriptomes 
(RNAseq) for each plant species, gathered from up to twenty tissue/organ samples that 
have experienced varied growth conditions and developmental histories, were analyzed in 
parallel. Three case studies illustrate different ways that the data can be integrally used to 
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generate testable hypotheses concerning the biochemistry, phylogeny and natural product 
diversity of medicinal plants. Deep metabolomics analysis of Camptotheca acuminata 
exemplifies how such data can be used to inform metabolic understanding of natural 
product chemical diversity and begin to formulate hypotheses about their biogenesis. 
Metabolomics data from Prunella vulgaris, a species that contains a wide range of 
antioxidant, antiviral, tumoricidal and anti-inflammatory constituents, provide a case study 
of obtaining biosystematic and developmental fingerprint information from metabolite 
accumulation data in a little studied species. Digitalis purpurea, well known as a source of 
cardiac glycosides, is used to illustrate how integrating metabolomics and transcriptomics 
data can lead to identification of candidate genes encoding biosynthetic enzymes in the 
cardiac glycoside pathway. Medicinal Plant Metabolomics Resource (MPM) [1] provides a 
framework for generating experimentally testable hypotheses about the metabolic networks 
that lead to the generation of specialized compounds, identifying genes that control their 
biosynthesis and establishing a basis for modeling metabolism in less studied species. The 
database is publicly available and can be used by researchers in medicine and  
plant biology.  
Keywords: database; metabolomics; specialized metabolites; medicinal; cardiac glycoside; 
alkaloid; digitalis; terpene; phenolic 
 
1. Introduction 
Humans have relied for millennia on natural products for relief of pain and improvement of health. 
Specialized metabolites from plants serve as rich resources for drug development. The molecular and 
physiological effects of medicinal plant extracts and components are often characterized in research 
studies of mammalian systems; almost 100 plant-derived compounds were in clinical trials in 2007, 
and as of 2008, 68% of all pharmaceuticals were plant derived or plant inspired [2].  
In part because they lack mobility, plants have evolved chemically-based strategies for defense and 
attraction [3,4]. As a consequence, even low levels of tens of thousands of the hundreds of thousands 
of metabolites that are synthesized across the plant kingdom interact with mammalian signaling 
networks via variety of molecular mechanisms. However, metabolic diversity is poorly characterized 
for most species that are used medicinally and indeed for plants in general. In addition, understanding 
of the molecules and metabolic pathways that lead to the formation of already-known plant-derived 
medicinal compounds is still incomplete. Modeling of metabolism requires computational technologies 
acting on multidimensional data, integrated with informed biological understanding of metabolites and 
pathways. In the case of medicinal plants (i.e., non-model-species), such data are scarce and difficult to 
integrate into a meaningful biological framework. One feature that can facilitate studies of plant 
metabolites and the corresponding pathways is that the content and profile of metabolite accumulation 
vary widely with developmental stage, cell and tissue type, genotype, and environmental perturbation 
[5–7]. A metabolomics-based analysis of natural products across multiple conditions is a first step 
Metabolites 2012, 2 1033 
 
towards elucidating the associated metabolic pathways and identifying enzymatic and regulatory genes 
associated with these pathways.  
The development of publicly-available genomic, transcriptomic, and more recently, metabolomic, 
flux and proteomic data sets for model organisms has accelerated the understanding of metabolism and 
metabolic networks [2,8–14]. Analogous data sets for medicinal plants will similarly revolutionize 
how researchers approach, decipher, and model the accumulation of medicinal compounds, and 
consequently enable the more effective development and utilization of medicinally active plant 
metabolites. This manuscript describes an information-rich database platform for medicinal plants 
(Medicinal Plant Metabolomics Resource (MPMR ， [1]) assembled through a large-scale, 
collaborative effort, and illustrates how such an investment can impact many who work in the fields of 
medicinal plant chemistry, biochemistry, metabolic modeling, and drug development. This resource is 
linked to transcriptomics data for the same samples (Medicinal Plant Metabolomics Resource 
(MPGR;[15]). The overall effort is part of the Medicinal Plant Consortium (MPC), an NIH-supported 
project including 13 collaborating research units from 7 institutions focused on 
providing transcriptomic [15] and metabolomic [1] resources for 14 key medicinal plants to the 
worldwide research community for the advancement of drug production and development. 
 MPMR is meaningful to the wider research community because it is available to all researchers for 
evaluation. A major challenge in evaluating complex datasets is how to best visualize these data to 
readily extract new knowledge. Here, we detail the public database MPMR, and we illustrate with test 
cases as to how the MPMR database can be used to extract information and provide a framework for 
researchers to generate experimentally testable hypotheses about the metabolites and metabolic 
networks that lead to the generation of specialized compounds.  
2. Results and Discussion 
Metabolomics data represent deep and comprehensive measures of the levels of metabolites in a 
defined tissue. In order for metabolomics data to be seamlessly integrated with other global molecular 
datasets that define the biological status of tissue(s), it needs to be organized and normalized in a 
standard format that enables cross-referencing with multiple datasets. Integral to this organization are 
the associated metadata that define the biological status of the tissue under analysis, and the methods 
used to extract and analyze the metabolites. The MPMR database and interface provide the ability to 
organize metabolomics data and metadata. The user interface and tools for MPMR were shaped in part 
by discussions among various participants of the MPC.  
Researchers can investigate the data using the tools within MPMR, or download it for additional 
statistical or bioinformatics analysis. These data can inform researchers who are planning detailed 
biochemical studies or who are devising a framework for a metabolic model for a medicinal plant species.  
An analytical approach to metabolomics used for many species in MPMR is Liquid 
Chromatography-Time-Of-Flight Mass Spectrometry (LC/TOF-MS); this method employs an 
information-rich strategy, termed multiplexed collision-induced dissociation (multiplexed CID) 
[16,17] that acquires mass spectra from 4 (or 5) different collision energies on the time-frame of 
ultrahigh performance liquid chromatography (UHPLC). LC/TOF-MS generates accurate molecular 
and fragment masses for all detected compounds, including low abundance intermediates, and yielded 
lists of several hundred to several thousand detected signals for each sample [18]. In deep metabolite 
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profiling of plant material, the number of detected metabolites far outstrips the number of known 
natural products.  
 
Figure 1. Scatterplots providing a rapid method for assessing the quality of metabolite 
determinations. 
 
 
Both panels are screenshots from MPMR. Upper panel: This example is from the Help section of 
MPMR, and contains an explanation of the plot features. The high scatter (low reproducibility) of 
data across the replicates from this sample might lead a user to considerable caution over data 
interpretation. Lower panel: The data from this sample have low scatter; replicates are quite similar 
to each other (Spearman correlation of 0.96–0.98).  
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In addition, a variety of Gas Chromatography-Mass Spectrometry (GC-MS) protocols were used for 
metabolite analysis. These incorporate a more targeted approach designed to highlight classes of 
known metabolites. The GC-MS platforms may detect hundreds of metabolites, many of which are 
also not identified. 
Metabolomic analysis of medicinal plant samples yields a rich resource of information, and one that 
is often ripe with surprises. To enable these data to be used by the community, the data are exported to 
and accessible through MPMR. Metadata describing the plant material, extraction, separation and 
analytical techniques are added. Various features are incorporated into MPMR to facilitate data 
exploration. An interactive comparison of the replicates of each organ analyzed, using scatterplots 
representing pairwise comparisons of replicates combined with Spearman correlations and bar graphs, 
enables the user to quickly assess the general quality of the data (Figure 1). MPMR can be searched by 
key words and molecular masses, and the data can be sorted in a variety of ways. Linked plots and 
tables enable the user to track the data from various vantage points. Three case studies of how MPMR 
can be used to inform a researcher are presented. 
2.1. Case Study: Deep Metabolic Profiling of Camptotheca acuminata as an Approach for 
Development of Hypotheses about the Camptothecin Biosynthesis Network 
LC/TOF-MS analyses of C. acuminata Decne. (Cornaceae) (Chinese happy tree, source of the 
anticancer compound camptothecin) revealed more than 50 abundant peaks, with more than 1900 
additional signals extracted into the metabolite database. Camptothecin is a quinoline alkaloid derived 
from an indole terpene alkaloid biosynthetic pathway [19]. The early steps in camptothecin 
biosynthesis involve formation of terpenoid precursors (through 10-hydroxygeraniol) and tryptamine, 
and these pathways must converge to form more complex intermediates (Figure 2). However, evidence 
for intermediate steps in the pathway has remained elusive, with several putative intermediates missing 
from the most extensive literature report of C. acuminata metabolite profiles [20].  
 
Figure 2. Proposed steps in the intermediate and late stages of camptothecin biosynthesis. 
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The complexity of the C. acuminata metabolome is reflected in Figure 3, which displays an 
LC/TOF-MS chromatogram of a bark extract. One of the more interesting realizations derived from 
these data is that several key intermediates were present as mixtures of isomers, and in many cases, 
abundances of fragment ions were not sufficient to distinguish these isomers. In the latter stages of the 
pathway, pairs of isomers were detected for strictosamide, pumiloside, deoxypumiloside, and other 
metabolites including a putative ketolactam. The isomeric metabolites have yet to be purified for 
complete structure elucidation, but one possibility is that they are stereoisomers with different 
configurations at the 3-position. The similarity in the ratios of isomers indicates that enzymes that 
catalyze these transformations may not exhibit much stereoselectivity in substrates.  
 
Figure 3. UHPLC/TOF-MS profile of metabolites extracted from C. acuminata bark. 
 
Chromatographic peaks are annotated with retention times and the mass of the most abundant ion 
in the corresponding mass spectrum. Multiple isomers were observed for secologanin, 
deoxypumiloside, pumiloside, and several other metabolites upstream of camptothecin. 
 
A rapid way to compare the difference between two datasets is a volcano plot, and we have found 
this approach to be very useful for visualizing metabolomics datasets and quickly identifying 
metabolites that are significantly altered between the two datasets (Figure 4). In these plots, the ratio of 
the abundance of each analyzed metabolite is calculated between two samples; this ratio is plotted on 
the x-axis. The metabolomics data are analyzed statistically using a t-test, and each metabolite is 
placed according to its P-value on the y-axis. Figure 4 represents metabolite abundances in young bark 
versus immature leaves (25-75% expanded). This plot indicates that a subset of alkaloids, and all of the 
detected alkaloid glycosides, are more abundant in young bark; however, several isomers of 
camptothecin are more predominant in young leaves. The plot also provides an indication of the 
statistical significance of the difference in abundance for each metabolite. 
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Figure 4. Volcano plots illustrating the difference in metabolite levels between bark and 
partially expanded young leaves, as shown in a screenshot from MPMR. 
 
The ratio of the abundance of each metabolite is calculated between two samples and plotted on the 
x-axis. Each symbol represents a different metabolite. The data were analyzed statistically within 
MPMR. Each metabolite is located according to its P-value on the y-axis. Metabolites in the pink 
shaded area are considered differentially accumulated according to their adjusted P-value, between 
the two samples. If the user mouses over a metabolite, additional information about that compound 
is shown (white inset box). 
 
Additional review of the Camptotheca metabolome reveals several more surprises. First, the 
proposed terpenoid intermediate secologanin [21,22] is barely detectable in any of the C. acuminata 
organs and tissues that we analyzed. This led us to conduct a follow-up analysis of several plant 
extracts, by using a slower UHPLC solvent gradient and a longer chromatographic column to better 
resolve isomeric metabolites (Figure 5). Extracted ion chromatograms for the [M+H]+ ion of 
secologanin contain two peaks corresponding to secologanin isomers with retention times that are 
distinct from an authentic secologanin standard and from the major secologanin isomer in an extract of 
Catharanthus roseus.  
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Figure 5. Extracted ion LC/MS chromatograms of [M+H]+ for (top) authentic secologanin 
standard, (middle) C. acuminata root extract, and (bottom) C. roseus RNA interference 
line of hairy root culture. The third peak in the latter two corresponds with secologanin, 
whereas the two earlier eluting peaks (in both C. acuminata and C. roseus) are isomers 
indistinguishable from molecular or fragment masses. 
 
2.2. Case Study 2: Using Metabolite Levels across Accessions and Organs of Prunella vulgaris to 
Investigate Intraspecific Diversity 
Commonly known as “selfheal” or “heal-all,” P. vulgaris L. (Lamiaceae) is a low-growing 
perennial herb native to a large part of the Northern Hemisphere. It is a relatively poorly characterized 
species that has recently been shown to have a wide variety of bioactivities. Its dried inflorescences 
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have a long history of use in traditional Asian and European medicine [23-26] as a remedy for cancer, 
sore throat, fever, and wounds. Recent data indicate that this species has potential to become an 
economically important medicinal herb through the wide scope of biological activities associated with 
P. vulgaris extracts [27-34]. Diverse bioactive compounds have been characterized from these 
extracts. Aqueous extracts display antioxidant, antiviral, tumoricidal and anti-inflammatory properties 
and are known to contain polyphenols and complex carbohydrates. P. vulgaris polysaccharides have 
exhibited antiviral, immunomodulatory and anti-tumorigenic activity [28,34-39], whereas phenolic 
constituents, such as rosmarinic acid, have antioxidant as well as immunomodulatory activity [33,40-
42]. Ethanolic extracts contain triterpenes and flavonoids [33,43,44], and several such compounds and 
extracts have significant anti-inflammatory activity [45,46].  
Because P. vulgaris has recently been shown to have a wide variety of bioactivities, but little 
research characterizes biochemical aspects of this species, the goal of this study was to provide 
information on metabolites across different accessions and developmental stages. These data would 
provide a potential basis for standardization for this species, and would enable a researcher to gain a 
quick understanding of what material they might want to employ in bioactivity assays or use to 
investigate the metabolic reactions and networks that lead to the specialized components. We also use 
the data to compare each accession by its metabolomic “fingerprint” and provide further understanding 
of their provenances. 
Figure 6. Variation in the breeding system of Prunella vulgaris can be visualized by this 
comparison of accessions Ames 29995 and PI 656839. 
 
A-C, exerted styles, which promote outcrossing, a relatively rare floral morphology in this species. 
D-F, the typical inserted-style phenotype. G, both phenotypes are known to shed pollen in-bud [47]. 
 
Typically, P. vulgaris populations display patterns of floral morphology that reflect a tendency 
towards self-pollination, but variants that promote outcrossing have also been noted (Figure 6) [47]. A 
mixed, but primarily autogamous, breeding system can result in the evolution of well-differentiated, 
local populations [48] that vary in adaptation, as noted in Prunella by Bocher [49], Nelson [50], 
Schmid  [51] and Winn and Gross [52], and this could include adaptations in metabolite composition. 
Brindley et al. [53] demonstrated that there is significant variation in antiviral properties among 
different P. vulgaris accessions cultivated under a common set of field conditions. In a separate study, 
the bioactive compound, rosmarinic acid, was evaluated in shoots of eleven P. vulgaris accessions; 
A B C 
D E F 
Inserted styles (PI 656839 from Iowa)  
Exerted styles (Ames 29995 from Japan) 
in‐bud pollen release G 
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these shoots were shown to differ by over 10-fold in concentrations of rosmarinic acid (Berhow et al., 
personal communication). These results indicate that there is likely a substantial genetic variation 
among P. vulgaris populations, at least for metabolites that would be likely to confer differences in 
bioactivity and pharmacological efficacy. Season of harvest can also influence metabolite composition, 
as evidenced by Chen et al. [54], who documented seasonal changes in rosmarinic, ursolic, and 
oleanolic acid concentrations in dried Prunella inflorescences.  
With the increasing emergence of information about the properties of this species in the last decade, 
P. vulgaris was incorporated into the medicinal plant germplasm collection conserved by the USDA-
ARS North Central Regional Plant Introduction Station (NCRPIS, Ames, IA) and from 2007 to 2011 
was one of three medicinal-plant genera being studied in Iowa by the Center for Research on Botanical 
Dietary Supplements[55]. Currently, the NCRPIS conserves 48 Prunella accessions from both Old and 
New World origins (USDA-ARS GRIN[56]).  
Five Prunella vulgaris accessions were chosen for metabolite fingerprinting analysis, based on 
diverse locations from which they were sourced (Table 1). Four of these accessions were originally 
sourced as wild populations from four different locations in North America, and one was collected 
from a site in Eastern Europe (South Ossetia, Georgia). Seeds collected from these populations were 
germinated and planted at the USDA North Central Regional Plant Introduction Station, Ames, IA. 
Figure 7 shows the appearance of these plants during the first two years of growth. By approximately 
3-months after planting, the Georgia accession (PI 664889) showed a clearly distinguishable 
morphological difference from the North American accessions; the former plants presenting a denser 
appearance. The majority of the plants did not flower during the first year of growth. However, in the 
second growth season, these plants flowered, and we collected intact aerial organs as illustrated in 
Figure 7. The organs that were subjected to metabolomics analyses were: shoots, cauline leaves, 
flowers, vegetative organs of shoots, and stems; metadata on these samples are provided at the MPMR 
database.  
Table 1. List of Prunella vulgaris accessions used in this study, their geographical origin 
and date of collection. All accessions were grown at the USDA Plant Introduction Station, 
Ames, IA. 
ACNO Place of collection Records 
PI 664873 (Ames 27664) North Carolina, United States 11/19/2004 
PI 664874 (Ames 27665) North Carolina, United States 11/19/2004 
PI 664875 (Ames 27666) North Carolina, United States 11/19/2004 
PI 664876 (Ames 27748) Missouri, United States 12/29/2004 
PI 664889 (Ames 29156) South Ossetia, Georgia 06/16/2008 
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Figure 7. Prunella vulgaris accessions growing at the Plant Introduction Station, Ames, IA. 
 
A at 3-months after planting; imaged summer 2009, and B during second year of growth; imaged 
on July 15th, 2010 at 11:00am, just before harvesting for metabolite analysis. Dissection of plant 
organs used for metabolomics analysis is illustrated with P. vulgaris accession PI 664874: C shoot, 
D cauline leaf, E flowers, F vegetative organs of shoot, G stem. 
2.2.1. Platforms Used in the Detection of Prunella Metabolites  
Fingerprint analysis of the metabolomes of the five Prunella accessions used a combination of 
metabolic profiling strategies: a non-targeted metabolomics analysis and three targeted metabolite-
profiling platforms. For non-targeted analysis, we used GC-MS based analysis of metabolite extracts. 
The advantage of this method is that it is highly sensitive, relatively easy to apply, and due to its 
history of use, chemical identification of detected compounds is facilitated by predictive rules of 
fragmentation during spectroscopy. This has led to the development of rigorous mass-spectral libraries, 
which facilitate chemical identification [57,58]. The limitation of this method is that only small 
PI 664873  PI 664874  PI 664875 PI 664876  PI 664889 A 
B 
C 
D 
E 
F 
G 
PI 664873  PI 664874  PI 664875 PI 664876  PI 664889 
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compounds, of less than about 1000 Da, can be analyzed, and chemical derivatization is needed to 
facilitate the volatilization of compounds into the gas-phase.  
The three targeted metabolite-profiling platforms that had previously been used in analyzing the 
metabolomes of Arabidopsis were used in these analyses, and they revealed the relative abundance of 
21 amino acids, 119 surface lipids, and 83 fatty acids, and the non-targeted metabolomics platform 
detected 222 metabolites (metadata via the extraction protocols and the identification of these 
metabolites are provided in the MPMR database). This approach of combining different analytical 
platforms enabled us to evaluate the relative abundance of nearly 450 Prunella metabolites. The 
rationale for combining non-targeted and targeted metabolite analysis is complex, and is aimed at 
maximizing the researcher’s ability to analytically access the “entire” metabolome of the samples, 
while also accurately annotating the chemical identities of many detected metabolites. We have 
chemically identified about 1/3 of the 450 Prunella metabolites that were detected, and most of these 
were detected in the targeted metabolite analysis platforms. Although network topologies can be best 
determined once chemical identities of metabolites are ascertained, all data can be used as a fingerprint 
to evaluate differences and similarities among the samples.  
2.2.2. Data Visualization and Evaluation of Prunella vulgaris 
The goal for this case study was to visualize the metabolites (out of the 450 that were evaluated) 
that accumulate at different levels among the different accessions and organs, and to use these data to 
evaluate the biological basis for these divergences. A ratio plot (Figure 8) is a standard method that 
enables an experimenter to focus on those metabolites that are most altered in abundance between two 
samples. Examples of such graphs are shown in Figure 8, which plots the ratio of metabolite 
abundances between cauline leaves and flowers in the five Prunella accessions. Additional insights 
into the chemical nature of the metabolites are provided by the color and shape of the symbol that is 
used to represent each metabolite in the graph, and the interactivity of the graph with the database. The 
experimenter can at a glance identify those metabolites that are most abundant in leaves (the ones that 
plot most distally from the x-axis origin in the positive direction), and those metabolites that are most 
abundant in flowers (the metabolites that plot most distally from the x-axis origin in the negative 
direction). This provides a quick look at the profile of each metabolite across the organs  
and accessions.  
However, while ratio plots are useful because of their simplicity, each one can only compare two 
samples. To analyze data using statistics specific for that dataset, we compare similar plots from all 
pairwise sample-set comparisons, and combine the resultant graphs. This provides a means of 
visualizing the data in an orthogonal manner. In all the graphs shown in Figure 8, the order of the 
metabolites on the y-axis is identical, and therefore one can directly compare all five graphs, and thus 
visualize the effect of genetic variation on the development of metabolic differences between leaves 
and flowers. A comparison of Figure 8D and Figure 8E is an example. Because the order of the 
metabolites on the y-axis is the same, these two graphs are directly comparable. The two panels plot 
plots of the log-ratio abundance of metabolites in leaves versus flowers in Prunella accessions PI 
664873 (8D) and PI 664889 (8E). It is immediately obvious that metabolites accumulate differentially 
in terms of their developmental profile (leaves versus flowers), but this developmental profile is likely 
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affected by the genetic diversity that is inherent in the two different accessions that are being 
compared.  
Figure 8. Differential accumulation of 340 metabolites between leaves and flowers among 
five different Prunella accessions. 
 
 
 
Figure 9 illustrates an approach to visually compare accessions based on relative metabolite 
abundances, and use these data as fingerprints to distinguish the metabolic differences among the five 
Prunella accessions. The ten graphs in this figure plot the relative abundance of all the detected 
metabolites in all organs assayed by using the abundance of the metabolites in each accession as the 
denominator in the calculation of the log-ratio values. In these graphs, the order of the metabolites is 
identical, and therefore the pattern of the graphs is directly comparable. Therefore, the metabolic 
relationship among the five accessions becomes a problem of pattern recognition – namely which two 
patterns are most similar or most different from the other. We used a combination of pattern-
recognition algorithms and statistical evaluations to address this question. 
   
‐7 0 7 ‐7 0 7 ‐7 0 7 ‐7 0 7 ‐7 0 7 
A B C D E 
A O
S S
 The coordinate on the x-axis of each graph plots the log(base 2)-ratio of the abundance of individual 
metabolites in leaves versus flowers.  The order of the metabolites on the y-axis is identical in all five 
graphs.  The five Prunella accessions are: PI 664873 A, PI 664874 B, PI 664875 C, PI 664876 D, and PI 
664889 E.  The 340 metabolites are categorized as: amino acids (    ), fatty acids (    ), organic acids (    ), 
phenolics (    ), sugars (    ), sugar acids (    ), sterols and triterpene  (    ), and chemically unidentified (    ).  
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Figure 9. Differential accumulation of 455 metabolites between different pairs of Prunella 
accessions.  
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2.2.3. Statistical analysis of the metabolomics data to evaluate systematic relationships among 
Prunella accessions. 
An approach to evaluate the metabolic profiling data is to integrate the relative abundance of all or a 
subset of the evaluated analytes, and calculate statistical distances among the biological samples (i.e., 
the five Prunella accessions). Although there are many choices of statistical distance measures, 
weighted Manhattan distance measure (Dij) is convenient, and has proven useful in analyzing 
metabolomics data [59-61]. The weighted Manhattan distance measure computes the dissimilarity 
between a pair of samples via the equation: 
Dij = 1k [|Yki - Ykj|/√[(Yki)2 + (Ykj)2]/K 
where: Dij is the weighted Manhattan distance between sample I and J; Yki is the abundance of 
metabolite k in sample I, and Ykj is abundance of metabolite k in sample J; K is the total number of 
metabolites. The term √[(Yki)2 + (Ykj)2] estimates the standard deviation of the difference in 
abundance. 
One property of this distance measure is its invariance to multiplicative rescaling of metabolite 
abundance data, which means the contribution of any metabolite to the value of Dij is the same no 
matter what the datum point determines (i.e., a peak area, a relative abundance, or an absolute 
concentration), as long as each of these quantities can be converted into another by multiplying by a 
constant factor. Moreover, each metabolite data point contributes equally to the calculation of the 
value of Dij irrespective of the magnitude of its abundance value. The statistical distance (Dij) between 
each pair of distinct samples ranges between zero and 1.0. When the two samples express the identical 
abundance for each metabolite the Dij = 0, and when the two samples have completely different 
constituents, Dij = 1.0.  
Based upon these distance calculations, relative statistical distances among the five Prunella 
accessions can be visualized by using multi-dimensional scaling (MDS) plots. The MDS plot of Figure 
10A represents 25 samples, composed of five experimental datasets generated from five Prunella 
accessions. In this plot, the distance between a pair of points represents the weighted statistical 
distance between a pair of Prunella samples based upon the profiling of the vegetative organs of 
shoots for cuticular lipids. The distances between points in the MDS plot are the best two-dimensional 
approximation to all pairs of Dij values in the distance matrix. This representation indicates that 
biological replicates with each accession cluster proximal to each other, and the underlying metabolic 
differences among these accessions can be used to distinguish each accession. Namely, of the 4 North 
 The coordinate on the x-axis of each graph plots the log(base 2)-ratio of the abundance of 
individual metabolites in the aerial organs of Prunella accessions.  The order of the metabolites on the 
y-axis is identical in all graphs.  Each graph compares the relative abundances of the metabolites in the 
following pairs of Prunella accessions:  PI 664873 versus PI 664876 A, PI 664874 versus PI 664876 
B, PI 664875 versus PI 664876 C, PI 664889 versus PI 664876 D, PI 664873 versus PI 664874 E, PI 
664875 versus PI 664874 F, PI 664889 versus PI 664874 G, PI 664875 versus PI 664873 H, PI 
664889 versus PI 664873 I, and PI 664875 versus PI 664874 J.    The 455 metabolites are categorized 
as: amino acids (    ), surface cuticular lipids (    ), alkenes (    ), ketones & esters (    ), fatty acids (     ), 
organic acids (    ), alcohols & phenolics (    ), sugars (    ), sterols & triterpens (    ), and chemically 
unidentified (    ).  
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American accessions, PI 664876, PI 664873 and PI 664874 resemble each other more closely than 
they do PI 664875, and these two groupings are equally distinct from the Georgian accession (PI 
664889). Although the latter would be expected based upon geographic provenance, and parallels the 
morphological differences among these accessions, the difference between PI 664875 and the other 
accessions is somewhat unexpected, and would not have been revealed without metabolic profiling.  
Figure 10. Statistical distances among Prunella accessions based upon cuticular lipid 
profiles from vegetative organs of shoots. 
 
A Multi-dimensional scaling (MDS) plot based on the statistical weighted Manhattan distance 
measure of cuticular lipid profiles from 3 to 6 biological replicates from each of the 5 Prunella 
accessions analyzed in this study. B K-means clustering of Prunella accessions based upon 
cuticular lipid profiles. Hierarchical clustering plot of the standardized abundances of cuticular 
lipid profiles of 3 to 6 biological replicates from each of the 5 Prunella accessions analyzed in this 
study. Data from the five Prunella accessions are color coded: Accession PI 664873 (yellow), 
Accession PI 664874 (blue), Accession PI 664875 (green), Accession PI 664876 (red), and 
Accession PI 664889 (purple). 
 
A similar conclusion about the relationships among the Prunella accessions is reached by a 
different statistical analysis of the cuticular lipid data, K-means clustering [62] of the standardized 
abundances. In this analysis, each abundance level was normalized by dividing each value with the 
maximum abundance of that metabolite in each sample. Hierarchical clustering of the standardized 
abundances identified three accession groups (Figure 10B). The most distinct cluster contains the 
biological replicates from the Georgian accession (PI 664889), and the samples from the North 
American accessions PI 664876, PI 664873 and PI 664874 cluster relatively closely together, whereas 
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accession PI 664875 is placed equidistant from the other two groups, a conclusion much like that 
reached from the MDS plot.  
2.3. Case Study: Combined Metabolomics and Transcriptomics of Digitalis purpurea for Hypothesis 
Development 
Cardenolides are a large and structurally diverse class of steroid derivatives found in select plant 
families, such as the Apocynaceae, but probably are more readily recognized for their association with 
foxglove (Digitalis species, Plantaginaceae) [63], and their therapeutic value as cardiac muscle 
stimulants [64]. For instance, Digitalis purpurea L. and D. lanata Ehrh. are credited as being some of 
the oldest herbal remedies for specific cardiac ailments, with a record of use dating from 1785 [65]. 
The biologically active chemicals found in Digitalis species were identified more than 50 years ago 
[66] and consist predominately of mono-, di- and tri-glycosides of specific steroid skeletons, such as 
digitoxigenin and digoxigenin (Figure 11). These compounds are still obtained by extraction from 
foxglove. 
 
Figure 11. Structure of cardenolides isolated from diverse Digitalis species. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The steroidal aglycones like digitoxigenin and digoxigenin differ in their hydroxylation patterns 
(red highlighting), while the glycosides consisting predominately of D-digitoxose residues added to 
the C3 hydroxyl along with a possible terminal D-glucose. 
 
Cardenolides belong to the larger chemical family of cardiac glycosides, which also include 
bufadienolides. Cardenolides and bufadienolides are both extremely toxic substances that possess 
multiple biological activities [64], but both are known to bind at nM concentrations to Na+/K+-
ATPases, sodium export transporters associated with maintenance of the ionic balance of ions across 
cell membranes [63,64] . Inhibition of these transporters strengthens the contraction of cardiac muscle 
cells at low, therapeutic concentrations, but is toxic and often lethal to many of the herbivores and 
other chewing pests [63] that attempt to consume the plants and animals producing cardiac glycosides 
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[67]. The major difference between these two classes of chemicals is that cardenolides contain a five-
membered lactone ring while the bufadienolides contain a six-membered lactone ring [64]. Equally 
intriguing, cardenolides are found largely in plants, while the bufadienolides are associated with skin 
glands of toxic toads [63]. As argued by Dobler et al. [63], given the structural similarities between the 
cardenolides and bufadienolides, the development of the biosynthetic machinery for cardenolides in 
plants and bufadienolides in amphibians may represent an example of convergent evolution. 
The pharmaceutical availability of cardenolides has depended upon their natural sources because of 
difficulties associated with their chemical syntheses [68]. Even more surprising is that the biosynthetic 
pathways for these diverse cardenolides have not been completely worked out, and there are numerous 
outstanding questions about their biosynthesis and accumulation. A better understanding of the 
biosynthetic pathway(s) per se should be useful in modeling cardenolide accumulation, in the design of 
molecular genetic screens to improve cardenolide end-product yield, and to develop plant lines 
accumulating a greater diversity of cardenolide products that could be screened for new or enhanced 
biological activities.  
 
Figure 12. A proposed pathway for digitoxin biosynthesis in Digitalis spp. 
 
Although experiments feeding intermediates have demonstrated that some of the proposed reactions 
do occur in planta and a few of the enzymes have actually been measured in in vitro assays [69], many 
of the steps depicted remain to be experimentally confirmed. Lanosterol is depicted as the first 
committed intermediate to cardenolide biosynthesis. Oxidosqualene is more commonly channeled to 
squalene
O
oxidosqualene
HOHO
H
H
H
HO
O
H
H
H
lanosterol
cholesterolpregnenolone
O
O
H
H
H
O
O
H
H
H
5-pregnan-3,20-dione
H HO
O
H
H
H
H
HO
O
H
H
OH
H
RO
H
H
OH
H
O O
RO
H
H
OH
H
O O
OH
RO
H
H
OH
H
O O
OH
progesterone
3-hydroxy-5-
pregnan-20-one
3, 14-dihydroxy-5-
pregnan-20-one
3, 14, 21-trihydroxy-
5-pregnan-20-one
digitoxigenin
HO
O
H
H
OH
H
OH
digoxigeningitoxigenin
Epoxidase
Synthase
Reductase
Demethylase
OxidaseSCCE
Dehydrogenase
Isomerase
Reductase
Oxido-
reductase Hydroxylase Hydroxylase
Hydroxylase
Hydroxylase
Malonyl-
transferase
Metabolites 2012, 2 1049 
 
cycloartenol, the well-established precursor to stigmasterol, sitosterol and campesterol, the dominant 
sterols found in all plants, rather than to lanosterol. However, only lanosterol and not cycloartenol has 
been demonstrated to be converted to cholesterol, and there is clear experimental precedent for the 
conversion of cholesterol to the pregnane family of steroids in mammals [64]. Hence, most depictions 
of the digitoxin biosynthetic pathway propose the lanosterol to cholesterol steps as intermediates, yet 
there is scant experimental evidence for this. Furthermore, only a couple of the genes encoding for 
enzymes in later steps of the pathway have been functionally characterized, such as that for the 
progesterone 5-reductase [64]. 
A putative, but partial pathway for cardenolide biosynthesis is shown in Figure 12; it is based 
largely on earlier precursor feeding studies and inferences taken from similar biochemical 
transformations occurring in mammalian steroidal biosynthetic pathways [69]. The proposed pathway 
also provides a means for directing attention to questions remaining to be resolved. For instance, are 
the cardenolides derived from cholesterol or perhaps are they derived from other phytosterol 
precursors, such as stigmasterol or sistosterol? While it has long been known that digitoxins 
accumulate in leaves, it is not clear if the site of synthesis differs from the site of accumulation. Are 
intermediates or end-products translocated between tissues? Once a biochemical pathway for 
digitoxins has been worked out, another question is how might cardenolide biosynthesis be regulated 
spatially and temporally relative to those pathways directing the sterol biosynthesis important for 
membrane biogenesis? Are there separate pathways localized to distinct intracellular compartments, or 
is there a central pipeline with bifurcation points where intermediates might be diverted to the 
biosynthesis of one class of sterols versus another?  
To address some of these questions, we developed metabolomics and transcriptomics resources for 
Digitalis with the long-range aim of applying these tools to define and validate a cardenolide 
biosynthetic pathway. Metabolite profiles assessed by high resolution LC/TOF-MS yielding 
approximately 2000 different metabolites were recorded for each plant extract, with metabolite 
validation from triplicate biological replications and duplicate technical replicates.  
Figure 13 provides screen shots from MPMR of the metabolic profile for select metabolites in 
various tissues of D. purpurea as a means for determining where cardenolides and putative 
intermediates might be accumulating. Four of the metabolites known for their pharmacological 
activities [63] were specifically monitored: digitoxigenin bis-digitoxoside; digitoxin; gitoxin; and 
glucodigitoxin. Interestingly, while all 4 of these metabolites have been found in leaf extracts [66], 
their distribution across diverse stages and organ types shows some striking differences. For instance, 
while digitoxigenin bis-digitoxoside levels in leaves are significant, much higher levels are observed in 
sepals and flowers (Figure 13A). In contrast, glucodigitoxin, another potent pharmacological 
compound, appears to accumulate preferentially in leaves with virtually none in sepals and lesser 
amounts in flowers (Figure 13B). Such an observation suggests that the glycotransferases specific for 
elaborating the digitoxigenin bis-digitoxoside to glucodigitoxin are present and active in leaves, but 
absent in sepals and only modestly in petals.  
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Figure 13. Levels of select cardenolides and putative biosynthetic intermediates in various 
tissues of Digitalis purpurea. 
 
Metabolites were extracted from the indicated tissues, profiled by high resolution LC/TOF-MS and 
their relative abundance determined as described at http://metnetdb.org/mpmr_public/. A 
digitoxigenin bis-digitoxoside (m/z 652.422); B digitoxin (m/z 782.477); C gitoxin (m/z 789.469); 
D glucodigitoxin (m/z 944.536); E lanosterol-like (m/z 427.324); F cholesterol-like (m/z 387.199). 
 
The D. purpurea metabolome was also screened for lanosterol-like and cholesterol-like metabolites 
likely to be intermediates in the pathway, with the idea that if the digitoxigenin steroid skeleton were 
synthesized in only one specific plant part, and then distributed throughout the plant for tissue-or 
organ-specific elaboration, one might expect these metabolites to accumulate exclusively in the region 
where their synthesis occurred. From the metabolite profiles (e.g., Figure 13E and F), this possibility 
seems unlikely. Instead, the lanosterol-like metabolites appear to be present almost exclusively (Figure 
13E) or, for the cholesterol-like metabolite, predominately (Figure 13F) in those plant parts where the 
cardenolides accumulate. These results would argue that the enzymes for lanosterol biosynthesis and 
the conversion of lanosterol to cholesterol should be present in all these tissues, and most abundant or 
active in leaf and floral tissues.  
We screened the D. purpurea transcriptome for candidates for genes encoding the enzymes 
responsible for the biosynthesis of lanosterol and its conversion to cholesterol, and then examined the 
relative abundance of each transcript in various organ types, as determined by a count of the number of 
respective sequence reads found for each assembled contig [15] (Figure 14). The progesterone 5-
reductase contigs served as a technical control in this analysis, because only this gene and one other 
relevant biosynthetic gene have been reported in the literature [70]. As illustrated in Figure 14, two 
independent contigs for the progesterone 5-reductase were identified, each of which differ somewhat 
from the progesterone 5-reductase gene previously characterized by Herl et al. [70]. The contigs 
A B 
C D 
E F 
Metabolites 2012, 2 1051 
 
identified in the D. purpurea transcriptome are more than 72% identical to the previously 
characterized gene, with their similarity exceeding 83%. The two contigs exhibit greater than 78% 
identity to one another.  
The apparent abundance of these two transcripts was contrary to our expectations from the 
metabolite-profiling analysis. Based on the relatively high level of end-product cardenolides in leaves 
and floral organs, we anticipated that the level of the progesterone 5--reductase transcript would 
mirror these metabolite levels. Instead, the reductase transcript level is constitutive across all the 
organs examined, which would suggest that some other step(s) in the pathway are rate-limiting for 
end-product cardenolide accumulation.  
The other question we posed of the D. purpurea transcriptome data is whether the expression level 
of genes for lanosterol and cholesterol biosynthesis are correlated with cardenolide accumulation. 
Essentially, we are asking if the steroidal skeleton of the cardenolides could be derived from a 
cholesterol precursor, consistent with the chemical rationalization for cardenolide biosynthesis (Figure 12).  
Two full-length triterpene synthase contigs were found when we queried the D. purpurea 
transcriptome with a lanosterol synthase gene from Arabidopsis [71]. The predicted proteins encoded 
from these contigs were 54 and 65% identical to the Arabidopsis lanosterol synthase, with similarity 
scores exceeding 70%. Interestingly, one of the contigs exhibited a relatively high level of expression 
in all tissue types, while the second contig demonstrated a lesser and variable abundance pattern. For 
instance, this second contig was more abundant in young or immature petioles, leaves, sepals and 
flowers than in the mature forms of these tissues. This sort of pattern might be consistent with a role 
for the enzyme encoded by this gene in cardenolide biosynthesis because metabolite accumulation 
commences in these immature tissues and continues on into the later stages of development.  
The conversion of lanosterol to cholesterol is a 19-step process requiring nine different enzymes, 
many of which participate in multiple steps and several that participate in analogous reactions at 
different points in the pathway [72]. When the D. purpurea transcriptome was queried for gene 
homologs coding for these enzymes, contigs for 7 of these genes were identified with multiple contigs 
found for the C4 sterol methyl oxidase (Figure 14). Contigs were not found for the C3 sterol 
dehydrogenase, nor for the C3 keto steroid reductase. Our survey of the D. purpurea transcriptome is 
by no means comprehensive or complete at this stage, because our screen was limited by the query 
sequences available for use. For instance, the transcriptome was screened for C3 keto steroid reductase 
contigs based on yeast and rat steroid reductase sequences, but no homologs were detected. This does 
not mean the C3 keto steroid reductase is absent from D. purpurea. It could be that such a gene arose 
independently with little or no sequence relationship to the yeast or rat genes, or that the genes have 
diverged widely in sequence.  
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Figure 14. The expression profile of contigs from D. purpurea with sequence similarity to 
cardenolide metabolic enzymes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The expression profiles are shown for contigs similar to lanosterol synthase (a triterpene synthase) 
and 7 of the 9 enzymes responsible for the conversion of lanosterol to cholesterol. The contigs 
similar to progesterone 5-reductase, a downstream enzyme in the cardenolide pathway that has 
been previously identified [70] are also shown. The contigs were identified by querying the D. 
purpurea transcriptome with sequences that had been previously identified in Arabidopsis, then 
using these contigs to determine their relative expression levels (fragments per 1,000 reads) from 
the D. purpurea expression matrix file downloadable from the MPGR website [15]. For triterpene 
synthase, C4 sterol methyloxidase, and progesterone 5-reductase, multiple full-length contigs 
were identified (the number of contigs is noted on figure). The D. purpurea contigs identified as 
homologs to the Arabidopsis counterpart: lanosterol synthase contig #s 2601 and 10,849; sterol 
14　-demthylase contig # 53,096; ∆14 sterol reductase contig # 483; sterol 4　-methyloxidase 
contig # 10,035; C4 sterol methyl oxidase contig #s 7,765, 213, 3,227; C8,7 sterol isomerase contig 
# 2,000; ∆24 sterol reductase contig # 14,785; C7 dehydrocholesterol reductase contig # 361; 
progesterone 5-reductase contig #s 14,174 and 17,397.  
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The transcript abundance profiles for these D. purpurea contigs were quite variable (Figure 14), and 
it is difficult to discern the extent to which any of the transcript profiles exhibited a pattern correlating 
with the accumulation patterns for the lanosterol or cholesterol-like metabolites (Figure 13). If 
anything, the transcript profiles would suggest that D. purpurea is likely to have the enzymological 
capacity for the conversion of lanosterol to cholesterol in many organs; ascertaining whether any of 
these enzymes are limiting or regulatory for cardenolide biosynthesis must await more detailed studies 
including measurement of the respective enzyme activities in each of these organ types.  
In summary, the combined analyses of these metabolomics and transcriptomics data have provided 
new insights into the biosynthetic pathways operating in D. purpurea and yielded testable hypotheses 
about the role of specific enzymes and genes in cardenolide metabolism. As such, this effort has 
helped to lay a foundation for the further enhancement of this plant species as a production platform 
for this important class of pharmaceuticals and the potential for its development as a source for new 
chemical entities addressing these and other medicinal needs.  
3. Experimental Section  
The metabolomes and transcriptomes of medicinal plant species were derived from analysis of up to 
20 different plant materials/treatments including major organ types and three developmental stages 
(young, immature and mature) for most taxa represented. For each species and experimental platform, 
detailed metadata about plant material, extraction, chromatography, and analytical and computer 
methodologies, are accessible from the corresponding section of the MPMR database. In brief, plant 
materials were harvested, quick frozen in liquid nitrogen and stored at -80°C until processing. Samples 
were extracted for metabolomic determinations by LC/TOF-MS according to Yeo et al [73]. 
(submitted), and in parallel for RNAseq [15]. For LC/TOF-MS analysis, peak detection, integration, 
and retention-time alignment used automated data processing, based on Waters MarkerLynx software. 
Export of peak areas was organized by definition of a measured signal based on mass-retention time 
pairs, individual metabolites were identified (when sufficient information exists) and their relative 
abundance measured on the basis of their molecular mass (atomic mass units) as reflected by their 
parent ion generated upon ionization, plus adducts with various salts (i.e. NH4+ and Na+) and, in 
special cases, possible oligomeric forms (i.e. twice the actual parent ion mass). For analysis by GC-
MS, compounds were extracted and analyzed by using targeted assays with known standards [14]. 
Data in MPMR are stored in a MySQL database. The data are accessed and sent to the client using 
server-side PHP code. Charts are created using the Javascript charting package Highcharts [74]. The 
site also uses JQuery [75] and Asynchronous Javascript and XML (AJAX; [76]) for both client-side 
features (the UI, for example, is based on JQueryUI) and server communications (JQuery's AJAX 
features are used for searching). 
4. Conclusions 
We describe a novel, publicly accessible database for medicinal plants, and its associated tools for 
identifying genes and developing metabolic models of specialized pathways. At present, the 
overwhelming majority of detected metabolites has yet to be annotated or identified. Such annotation 
is complicated by the existence of multiple isomers of putative key metabolic intermediates.  
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Measured metabolite levels provide an important resource for establishing functions of genes 
responsible for medicinal compound accumulation in plant tissues. This is particularly true in the case, 
as for most species in MPMR, when transcriptomics data have been gathered from the same samples 
that were metabolically assayed. 
The MPMR database itself can be considered a “live” resource. As methods for identification of 
additional compounds increase, detailed analyses of the raw data will enable additional progress. The 
data can inform modeling of the metabolic networks of specialized plant products both by the 
researchers who deposited the data and by the broader research community. Characterized metabolic 
pathways and networks are key to the metabolic engineering of natural product composition in the host 
species, and to develop effective microbial expression platforms for these and structurally-related 
compounds [3,6,77]. Moreover, combining genes of biosynthetic pathways from different medicinal 
plants will enable the generation of novel classes of compounds that may not otherwise occur in nature 
or be readily accessible by chemical synthesis. From a human-health perspective, these data and 
techniques can enable bioengineering of plants both to produce larger quantities of medicinally-useful 
compounds as well as to produce new specialized compounds with targeted therapeutic potentials. 
Furthermore, modeling of wild plant populations can provide insights into the evolution of plant 
natural products. Such models will benefit from a more complete understanding of the pathways and 
the extent of enzyme promiscuity, and will depend on ambitious efforts to isolate intermediates and 
establish their structures through NMR spectroscopy and/or x-ray crystallography.  
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